glp-1 receptor agonist kidney outcomes semaglutide flow trial 2024 results Comparative renal of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or agonists under routine care | Diabetologia CKJ REVIEW GLP-1 receptor agonists
Description
E.T.C.-L., B.T.B., P.R.R
High gastrointestinal discontinuation rates exceeding 50% across all doses, combined with liver safety signals in early studies, ultimately led Pfizer to discontinue danugliprons development in April 2025
The approach involves regular monitoring and support to ensure adherence and effectiveness
GLP-1 and adverse effects in specific populations Younger individuals
How does PlexusDx personalize GLP-1 treatment
